RapidEye
Regeneron Pharmaceuticals (NASDAQ:RAIN), maker of eye disease therapy Eylea, has acquired Oxular, a UK-based biotech drug maker focused on ophthalmology.
While neither company has officially disclosed the deal, former Oxular CEO Mark Gaffney, who currently leads Calluna Pharma's immune drug development, shared